More prospective clinical evidence is required to fully determine the benefits of ARBs, ACE inhibitors, CCBs, and metformin on survival in patients with pancreatic cancer before treatment recommendations can be made regarding their use, duration, and dosage in the broader target population. Here, ACE is linked to pancreatic neoplasm.